A Phase I Study of TNO155 to treat Advanced Solid Tumors

Full Title

TNO155: An Open-Label, Multi-Center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients with Advanced Solid Tumors

Purpose

The purpose of this study is to find the highest dose of an investigational drug called TNO155 that can be given safely in patients with advanced solid tumors. TNO155 works by blocking enzymes called phosphatases that cancer cells use to grow and spread. TNO155 is a pill that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor which cannot be cured with standard therapies. Patients must have one of these tumor types to participate in the dose-escalation portion of the study: EGFR-mutant non-small cell lung cancer; head and neck cancer; colorectal cancer that does not contain KRAS, NRAS, or BRAF mutations; or GIST tumors.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Helena Yu at 646-888-4274.

Protocol

17-266

Phase

I

Investigator

Co-Investigators